Share Twitter LinkedIn Facebook Email Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment Non-Small Cell Lung Cancer 5 Mins Read
Plasma ctDNA Kinetics as a Predictor of Systemic Therapy Response in Advanced NSCLC Non-Small Cell Lung Cancer 3 Mins Read
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read